196 related articles for article (PubMed ID: 33567428)
1. Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.
Ochiai Y; Iizuka T; Hoshihara Y; Suzuki Y; Hayasaka J; Nomura K; Tanaka M; Odagiri H; Yamashita S; Matsui A; Kikuchi D; Ueno M; Udagawa H; Hoteya S
Dig Dis; 2021; 39(6):569-576. PubMed ID: 33567428
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
Mizuno H; Nishino M; Yamada K; Kamiyamamoto S; Hinoue Y
Digestion; 2020; 101(4):411-421. PubMed ID: 31129668
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
Zhuang Q; Chen S; Zhou X; Jia X; Zhang M; Tan N; Chen F; Zhang Z; Hu J; Xiao Y
Am J Gastroenterol; 2024 May; 119(5):803-813. PubMed ID: 38345252
[TBL] [Abstract][Full Text] [Related]
9. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
[TBL] [Abstract][Full Text] [Related]
11. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A
Digestion; 2021; 102(3):480-488. PubMed ID: 32062650
[TBL] [Abstract][Full Text] [Related]
12. Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis.
Takenouchi N; Hoshino S; Hoshikawa Y; Tanabe T; Koeda M; Momma E; Ishikawa Y; Kawami N; Kaise M; Iwakiri K
Esophagus; 2020 Jan; 17(1):87-91. PubMed ID: 31679094
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors for medication-refractory reflux esophagitis in patients with systemic sclerosis in Japan.
Kuribayashi S; Nakamura F; Motegi SI; Hara K; Hosaka H; Sekiguchi A; Ishikawa M; Endo Y; Harada T; Sorimachi H; Obokata M; Uchida M; Yamaguchi K; Uraoka T
J Gastroenterol; 2024 Mar; 59(3):179-186. PubMed ID: 38252140
[TBL] [Abstract][Full Text] [Related]
14. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Habu Y
Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Vonoprazan-Treated Patients after Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Multicenter Observation Study.
Ishida T; Dohi O; Yamada S; Yasuda T; Yamada N; Tomie A; Tsuji T; Horii Y; Majima A; Horie R; Fukui A; Zen K; Tomatsuri N; Yagi N; Naito Y; Itoh Y
Digestion; 2021; 102(3):386-396. PubMed ID: 32585678
[TBL] [Abstract][Full Text] [Related]
16. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Iwakiri K
J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
Kinoshita Y; Hongo M;
Am J Gastroenterol; 2012 Apr; 107(4):522-30. PubMed ID: 22433921
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis.
Umezawa M; Kawami N; Hoshino S; Hoshikawa Y; Koizumi E; Takenouchi N; Hanada Y; Kaise M; Iwakiri K
Digestion; 2018; 97(4):309-315. PubMed ID: 29514137
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China.
Wang Z; Sun R; Sheng Y; Qu S; Dong L; Wu B
Ann Transl Med; 2022 Apr; 10(8):480. PubMed ID: 35571388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
